Microba Life Sciences Stock Revenue
| MAP Stock | 0.19 0.01 5.56% |
Microba Life Sciences fundamentals help investors to digest information that contributes to Microba Life's financial success or failures. It also enables traders to predict the movement of Microba Stock. The fundamental analysis module provides a way to measure Microba Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Microba Life stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 12.1 M | 12.7 M |
Microba | Revenue |
Microba Life Sciences Company Revenue Analysis
Microba Life's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Microba Life Revenue | 12.09 M |
Most of Microba Life's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Microba Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Microba
Projected quarterly revenue analysis of Microba Life Sciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Microba Life match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Microba Life's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Microba Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Microba Life Sciences reported 12.09 M of revenue. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The revenue for all Australia stocks is notably lower than that of the firm.
Microba Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Microba Life's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Microba Life could also be used in its relative valuation, which is a method of valuing Microba Life by comparing valuation metrics of similar companies.Microba Life is currently under evaluation in revenue category among its peers.
Microba Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.65) % | ||||
| Operating Margin | (1.31) % | ||||
| Current Valuation | 61.31 M | ||||
| Shares Outstanding | 447.85 M | ||||
| Shares Owned By Insiders | 54.55 % | ||||
| Shares Owned By Institutions | 22.83 % | ||||
| Price To Book | 1.96 X | ||||
| Price To Sales | 6.67 X | ||||
| Revenue | 12.09 M | ||||
| Gross Profit | 2.68 M | ||||
| EBITDA | (17.1 M) | ||||
| Net Income | (19.94 M) | ||||
| Cash And Equivalents | 12.43 M | ||||
| Total Debt | 1.58 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (15.57 M) | ||||
| Earnings Per Share | (0.05) X | ||||
| Target Price | 0.34 | ||||
| Beta | 2.7 | ||||
| Market Capitalization | 80.61 M | ||||
| Total Asset | 58.04 M | ||||
| Retained Earnings | (63.82 M) | ||||
| Working Capital | 33.7 M | ||||
| Net Asset | 58.04 M |
About Microba Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Microba Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microba Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microba Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Microba Stock Analysis
When running Microba Life's price analysis, check to measure Microba Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microba Life is operating at the current time. Most of Microba Life's value examination focuses on studying past and present price action to predict the probability of Microba Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microba Life's price. Additionally, you may evaluate how the addition of Microba Life to your portfolios can decrease your overall portfolio volatility.